Selected research
Industry Research
Brain Disease Modalities And Software Industry Research Report 2026
Market perspective
The global Brain Disease Modalities And Software market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Brain Disease Modalities And Software market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Brain Disease Modalities And Software market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Brain Disease Modalities And Software market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Brain Disease Modalities And Software include Quantib, Brainomix, General Electric, Imaging Biometrics, United Imaging Healthcare Co, Siemens, Healthineers AG, Koninklijke Philips N.V. and Canon, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Brain Disease Modalities And Software market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Brain Disease Modalities And Software.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Brain Disease Modalities And Software Market by Company
Quantib
Brainomix
General Electric
Imaging Biometrics
United Imaging Healthcare Co
Siemens
Healthineers AG
Koninklijke Philips N.V.
Canon
Vuno
Aspect Imaging
IXICO
QMENTA
I. Analysis
Fujifilm Holdings
Other Prominent Players
Brain Disease Modalities And Software Segment by Type
Brain Imaging Modalities
Brain Analysis Software
Brain Disease Modalities And Software Segment by Application
Adults
Pediatrics and Infants
Brain Disease Modalities And Software Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Brain Disease Modalities And Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Brain Disease Modalities And Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Brain Disease Modalities And Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Brain Disease Modalities And Software companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Brain Imaging Modalities
- Brain Analysis Software
Applications
- Adults
- Pediatrics and Infants
Companies covered
- Quantib
- Brainomix
- General Electric
- Imaging Biometrics
- United Imaging Healthcare Co
- Siemens
- Healthineers AG
- Koninklijke Philips N.V.
- Canon
- Vuno
- Aspect Imaging
- IXICO
- QMENTA
- I. Analysis
- Fujifilm Holdings
- Other Prominent Players
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Brain Disease Modalities And Software by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Brain Imaging Modalities
- 2.2.3 Brain Analysis Software
- 2.3 Brain Disease Modalities And Software by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Adults
- 2.3.3 Pediatrics and Infants
- 2.4 Assumptions and Limitations
3 Brain Disease Modalities And Software Breakdown Data by Type
- 3.1 Global Brain Disease Modalities And Software Historic Market Size by Type (2021-2026)
- 3.2 Global Brain Disease Modalities And Software Forecasted Market Size by Type (2027-2032)
4 Brain Disease Modalities And Software Breakdown Data by Application
- 4.1 Global Brain Disease Modalities And Software Historic Market Size by Application (2021-2026)
- 4.2 Global Brain Disease Modalities And Software Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Brain Disease Modalities And Software Market Perspective (2021-2032)
- 5.2 Global Brain Disease Modalities And Software Growth Trends by Region
- 5.2.1 Global Brain Disease Modalities And Software Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Brain Disease Modalities And Software Historic Market Size by Region (2021-2026)
- 5.2.3 Brain Disease Modalities And Software Forecasted Market Size by Region (2027-2032)
- 5.3 Brain Disease Modalities And Software Market Dynamics
- 5.3.1 Brain Disease Modalities And Software Industry Trends
- 5.3.2 Brain Disease Modalities And Software Market Drivers
- 5.3.3 Brain Disease Modalities And Software Market Challenges
- 5.3.4 Brain Disease Modalities And Software Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Brain Disease Modalities And Software Players by Revenue
- 6.1.1 Global Top Brain Disease Modalities And Software Players by Revenue (2021-2026)
- 6.1.2 Global Brain Disease Modalities And Software Revenue Market Share by Players (2021-2026)
- 6.2 Global Brain Disease Modalities And Software Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Brain Disease Modalities And Software Head Office and Area Served
- 6.4 Global Brain Disease Modalities And Software Players, Product Type & Application
- 6.5 Global Brain Disease Modalities And Software Manufacturers Established Date
- 6.6 Global Brain Disease Modalities And Software Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Brain Disease Modalities And Software Market Size (2021-2032)
- 7.2 North America Brain Disease Modalities And Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Brain Disease Modalities And Software Market Size by Country (2021-2026)
- 7.4 North America Brain Disease Modalities And Software Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Brain Disease Modalities And Software Market Size (2021-2032)
- 8.2 Europe Brain Disease Modalities And Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Brain Disease Modalities And Software Market Size by Country (2021-2026)
- 8.4 Europe Brain Disease Modalities And Software Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Brain Disease Modalities And Software Market Size (2021-2032)
- 9.2 Asia-Pacific Brain Disease Modalities And Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Brain Disease Modalities And Software Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Brain Disease Modalities And Software Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Brain Disease Modalities And Software Market Size (2021-2032)
- 10.2 South America Brain Disease Modalities And Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Brain Disease Modalities And Software Market Size by Country (2021-2026)
- 10.4 South America Brain Disease Modalities And Software Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Brain Disease Modalities And Software Market Size (2021-2032)
- 11.2 Middle East & Africa Brain Disease Modalities And Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Brain Disease Modalities And Software Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Brain Disease Modalities And Software Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Quantib
- 12.1.1 Quantib Company Information
- 12.1.2 Quantib Business Overview
- 12.1.3 Quantib Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.1.4 Quantib Brain Disease Modalities And Software Product Portfolio
- 12.1.5 Quantib Recent Developments
- 12.2 Brainomix
- 12.2.1 Brainomix Company Information
- 12.2.2 Brainomix Business Overview
- 12.2.3 Brainomix Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.2.4 Brainomix Brain Disease Modalities And Software Product Portfolio
- 12.2.5 Brainomix Recent Developments
- 12.3 General Electric
- 12.3.1 General Electric Company Information
- 12.3.2 General Electric Business Overview
- 12.3.3 General Electric Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.3.4 General Electric Brain Disease Modalities And Software Product Portfolio
- 12.3.5 General Electric Recent Developments
- 12.4 Imaging Biometrics
- 12.4.1 Imaging Biometrics Company Information
- 12.4.2 Imaging Biometrics Business Overview
- 12.4.3 Imaging Biometrics Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.4.4 Imaging Biometrics Brain Disease Modalities And Software Product Portfolio
- 12.4.5 Imaging Biometrics Recent Developments
- 12.5 United Imaging Healthcare Co
- 12.5.1 United Imaging Healthcare Co Company Information
- 12.5.2 United Imaging Healthcare Co Business Overview
- 12.5.3 United Imaging Healthcare Co Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.5.4 United Imaging Healthcare Co Brain Disease Modalities And Software Product Portfolio
- 12.5.5 United Imaging Healthcare Co Recent Developments
- 12.6 Siemens
- 12.6.1 Siemens Company Information
- 12.6.2 Siemens Business Overview
- 12.6.3 Siemens Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.6.4 Siemens Brain Disease Modalities And Software Product Portfolio
- 12.6.5 Siemens Recent Developments
- 12.7 Healthineers AG
- 12.7.1 Healthineers AG Company Information
- 12.7.2 Healthineers AG Business Overview
- 12.7.3 Healthineers AG Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.7.4 Healthineers AG Brain Disease Modalities And Software Product Portfolio
- 12.7.5 Healthineers AG Recent Developments
- 12.8 Koninklijke Philips N.V.
- 12.8.1 Koninklijke Philips N.V. Company Information
- 12.8.2 Koninklijke Philips N.V. Business Overview
- 12.8.3 Koninklijke Philips N.V. Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.8.4 Koninklijke Philips N.V. Brain Disease Modalities And Software Product Portfolio
- 12.8.5 Koninklijke Philips N.V. Recent Developments
- 12.9 Canon
- 12.9.1 Canon Company Information
- 12.9.2 Canon Business Overview
- 12.9.3 Canon Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.9.4 Canon Brain Disease Modalities And Software Product Portfolio
- 12.9.5 Canon Recent Developments
- 12.10 Vuno
- 12.10.1 Vuno Company Information
- 12.10.2 Vuno Business Overview
- 12.10.3 Vuno Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.10.4 Vuno Brain Disease Modalities And Software Product Portfolio
- 12.10.5 Vuno Recent Developments
- 12.11 Aspect Imaging
- 12.11.1 Aspect Imaging Company Information
- 12.11.2 Aspect Imaging Business Overview
- 12.11.3 Aspect Imaging Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.11.4 Aspect Imaging Brain Disease Modalities And Software Product Portfolio
- 12.11.5 Aspect Imaging Recent Developments
- 12.12 IXICO
- 12.12.1 IXICO Company Information
- 12.12.2 IXICO Business Overview
- 12.12.3 IXICO Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.12.4 IXICO Brain Disease Modalities And Software Product Portfolio
- 12.12.5 IXICO Recent Developments
- 12.13 QMENTA
- 12.13.1 QMENTA Company Information
- 12.13.2 QMENTA Business Overview
- 12.13.3 QMENTA Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.13.4 QMENTA Brain Disease Modalities And Software Product Portfolio
- 12.13.5 QMENTA Recent Developments
- 12.14 I. Analysis
- 12.14.1 I. Analysis Company Information
- 12.14.2 I. Analysis Business Overview
- 12.14.3 I. Analysis Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.14.4 I. Analysis Brain Disease Modalities And Software Product Portfolio
- 12.14.5 I. Analysis Recent Developments
- 12.15 Fujifilm Holdings
- 12.15.1 Fujifilm Holdings Company Information
- 12.15.2 Fujifilm Holdings Business Overview
- 12.15.3 Fujifilm Holdings Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.15.4 Fujifilm Holdings Brain Disease Modalities And Software Product Portfolio
- 12.15.5 Fujifilm Holdings Recent Developments
- 12.16 Other Prominent Players
- 12.16.1 Other Prominent Players Company Information
- 12.16.2 Other Prominent Players Business Overview
- 12.16.3 Other Prominent Players Revenue in Brain Disease Modalities And Software Business (2021-2026)
- 12.16.4 Other Prominent Players Brain Disease Modalities And Software Product Portfolio
- 12.16.5 Other Prominent Players Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst